Actelion declines Trophos option as olesoxime crashes in Phase III
This article was originally published in Scrip
Executive Summary
Trophos' lead compound, olesoxime, has failed a Phase III study in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). As a result, Actelion will not be exercising its option to acquire Trophos under a €10 million acquisition option agreement signed last year (scripintelligence.com, 20 July 2010).